Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive treatment option for patients with severe aortic stenosis (narrowing of the aortic valve). The Emory TAVR program began in 2007 within the PARTNER I clinical trial and to-date over 2,500 patients have received this groundbreaking therapy at Emory HealthCare.

Kendra Grubb, MD, discusses TAVR, and why you might consider this treatment option.